|
|
|
|
There are novel agents in the pipeline for diabetes
In the next few years, the treatment of diabetes may change dramatically. If just some of the drugs in phase III trials fulfill their current promise and reach market, we may see the following developments. Pinch yourself. These things are really happening in diabetes therapy—and happening fast.
|
| |
More>>
|
|
|
|
|
|
Make way for a new era of insulin therapy
Insulin therapies have evolved to the point where Drs. Frederick Banting and Charles Best would hardly recognize their own discovery. With the advent of modern recombinant DNA technology, scientists have developed insulin analogs that better mimic the body's normal insulin action. Now, more predictable basal and bolus insulin therapies help achieve tighter glucose control.
|
| |
More>>
|
|
|
|
|
|
Rapid- and slow-acting insulins help control diabetes
If the united states' healthcare trend continues on its current course, in 20 years the number of people with diabetes will more than double to 50 million. This dismaying prediction comes from a new report from the Yale Schools of Public Health and Medicine in conjunction with the Institute for Alternative Futures. If the current trend continues, by 2025.
|
| |
More>>
|
|
|
|
|
|
DERMATOLOGY CASE CHALLENGE: A diabetic patient with longstanding, expanding pretibial plaques
A 37-year-old woman presents with plaques of 1 year's duration on her lower legs that appear to be expanding. The patient has a history of poorly controlled diabetes mellitus requiring insulin but is otherwise well and taking no other medications. The clinician suspects granuloma annulare, cellulitis, sarcoidosis, xanthomas, necrobiosis lipoidica diabeticorum, and necrobiotic xanthogranuloma.
|
| |
More>>
|
|
|
